Published February 26, 2021 | Version v1
Journal article Open

Effective, safe and rational pharmacotherapy of endogenic progesterone deficiency

Creators

  • 1. SI «Dnepropetrovsk medical academy Ministry of Health of Ukraine»

Description

Today, the most frequent complication of pharmacotherapy is an allergic reaction, the so-called drug or drug allergy. An allergic reaction can be caused both by the active ingredients and by the excipients included in the composition of the drug to provide a certain dosage form and its physicochemical properties. Vaginal progesterone preparations are characterized by a large variety of dosage forms: gels, tablets and gelatin capsules for intravaginal administration. It is known that the safety and efficacy of pharmacotherapy depend on the active substance, the dosage form, and the base of the intravaginal preparation, as well as the indices of adherence to medication therapy. At the same time, the base - excipients can cause the development of adverse reactions.
The authors of the article, based on an analytical review of domestic and foreign literature, analyzed effective, safe and rational pharmacotherapy of endogenous progesterone deficiency.
It is shown that micronization is currently used to improve the bioavailability of natural progesterone – a method of increasing solubility by reducing the particle size of the drug substance. Due to the high solubility of the substance, the risk of possible side effects is reduced, which allows increasing the safety of the drug.
The peculiarity of the dosage form for vaginal administration is described. On the basis of the analysis of various forms of progesterone, the clinical efficacy of natural progesterone for vaginal administration has been substantiated.
The authors found that the use of progesterone in sublingual and vaginal forms is the most rational in terms of convenience, efficacy and safety.

Files

Effective, safe and rational pharmacotherapy of endogenic progesterone deficiency.pdf

Files (261.3 kB)

Additional details

References

  • Безопасность лекарств. Руководство по фармаконадзору / Под ред. А.П. Викторова, В.И. Мальцева, Ю.Б. Белоусова. – К.: МОРИОН, 2007. – 240 с.
  • Новиков Д.К., Новикова В.И., Новиков П.Д. Аллергические реакции на лекарства и медикаменты. Пособие. – Витебск: ВГМУ, 2012. – 48 с.
  • Katz D.F., Yuan A., Gao Y. Vaginal drug distribution modeling. Adv Drug Deliv Rev. 2015;92:2–13. DOI: org/10.1016/j.addr.2015.04.017.
  • Food Allergen Labeling And Consumer Protection Act of 2004 (FALCPA) Public Law 108-282, Title II.
  • Food Allergen Labeling And Consumer Protection Act of 2004 (FALCPA) Public Law 108-282, Title I.
  • Kuzemchak S. The FDA Is Now Allowing a Peanut-Allergy Claim on Baby Food Packaging September 08, 2017.
  • FDA News Release FDA approves first drug for treatment of peanut allergy for children January 31, 2020.
  • Peanut Oil Allergy Factsheet Nov 2017Document Reference ACFS29Next review date Nov 2020©The Anaphylaxis Campaign 2012.
  • Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' 22 November 2019.
  • Different routes of progesterone administration and polycystic ovary syndrome: a review of the literature/ Unfer V, Casini ML, Marelli G, [et all.] // Gynecol Endocrinol. – 2005. – Vol. 21, № 2. – Р. 119–127.
  • Алексеев К.В. Технологические аспекты производства современных твердых лекарственных форм / К.В. Алексеев // Фармацевтические технологии и упаковка. Лекарства по GMP. – 2009.
  • Pharmacokinetics of natural proges terone administered in the form of a vaginal tablet / T. Levy, S. Gurevitch, I. Bar–Hava [et al.] // Hum. Reprod. – 1999. – Vol. 14, N 3. – Р. 606–610.
  • Опрышко В.И., Носивец Д.С. Инновации и тренды в клинической фармакологии вагинальных форм гестагенов // Медицинские аспекты здоровья женщины. – 2016. – № 5 (102). – С. 55–61.
  • Опрышко В.И., Носивец Д.С. Оригинальность форм микронизированного прогестерона // З турботою про Жінку. – 2016. – № 8 (74). – С. 10–11.